Dr. Richardson - Lenalidomide, Bortezomib, and Dexamethasone (Rev/Vel/Dex) as Front-Line Therapy for Patients with Multiple Myeloma (MM): Preliminary Resultsof a Phase 1/2 Study.
Paul Richardson, MD Jerome Lipper Myeloma Center Dana Farber Cancer Institute Boston, MA Member, IMF Board of Scientific Advisors
12.29.07
To view the video full screen, click on the small
button next to the volume control in the
lower right hand corner.
back
button next to the volume control in the
lower right hand corner.
print
related articles